Xeris Biopharma Holdings (XERS) concentration risks

Xeris Biopharma's concentration risk is entirely supply-side, and it is significant: the company relies on Regis Technologies' Illinois facility as its sole source for API and on Lonza Tampa's Florida facility as its sole source for drug product — two separate, high-share, single-point dependencies covering both the active ingredient and the finished product stages of manufacturing. A disruption at either facility would leave no immediately available alternative for that stage of production, since both are described as sole sources rather than one of several qualified suppliers. Two further dependencies exist at a somewhat smaller disclosed scale: Bachem Americas serves as the primary commercial source for glucagon API, and Pyramid Laboratories' California facility serves as a primary source for drug product — both important but described as "primary" rather than "sole" sources, suggesting somewhat more flexibility than the Regis and Lonza relationships. Taken together, Xeris's manufacturing chain runs through a small number of named, geographically dispersed facilities rather than a broadly diversified supplier base, with the sole-source Regis and Lonza relationships representing the larger, high-share single points of failure and the Bachem and Pyramid relationships representing a related but more moderate dependency.

For the engine’s reasoning on XERS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.